ANDA 204230, held by Apotex. Bendamustine Hydrochloride.
As of Nov 21, 2026, ANDA 204230 (Bendamustine Hydrochloride), held by Apotex, was first approved by FDA on Jun 5, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2023 | Original application | Approved |
| Bendamustine Hydrochloride25MG/VIAL · powder;intravenous | Bendamustine Hydrochloride | Discontinued |
| Bendamustine Hydrochloride100MG/VIAL · powder;intravenous | Bendamustine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters